Sofosbuvir Side Effects
Applies to sofosbuvir: oral packet, oral tablet.
Warning
Oral route (Tablet)
Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with sofosbuvir. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
Serious side effects of Sofosbuvir
Along with its needed effects, sofosbuvir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking sofosbuvir:
More common
- Chills
- fever
- lower back or side pain
- pale skin
- ulcers, sores, or white spots in the mouth
- unusual tiredness or weakness
Rare
- Changes in behavior
- discouragement
- feeling sad or empty
- loss of interest or pleasure
- thoughts of killing oneself
- trouble concentrating
Incidence not known
- Chest pain or discomfort
- lightheadedness, dizziness, or fainting
- shortness of breath
- slow or irregular heartbeat
- unusual tiredness
Other side effects of Sofosbuvir
Some side effects of sofosbuvir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Decreased appetite
- diarrhea
- difficulty with moving
- headache
- irritability
- lack or loss of strength
- muscle aching or cramping
- muscle pains or stiffness
- nausea
- rash or itching skin
- trouble sleeping
For Healthcare Professionals
Applies to sofosbuvir: oral pellet, oral tablet.
General
When this drug is used with ribavirin or peginterferon alfa/ribavirin, the respective manufacturer product information should be consulted for associated side effects.
The most common side effects reported with sofosbuvir and ribavirin therapy were fatigue and headache. The most common side effects reported with sofosbuvir, peginterferon alfa, and ribavirin therapy were fatigue, headache, nausea, insomnia, and anemia. Therapy was permanently discontinued due to side effects in up to 4% of subjects using placebo, up to 1% of subjects using sofosbuvir and ribavirin for 12 weeks, less than 1% of subjects using sofosbuvir and ribavirin for 24 weeks, 11% of subjects using peginterferon alfa and ribavirin for 24 weeks, and 2% of subjects using sofosbuvir, peginterferon alfa, and ribavirin for 12 weeks.[Ref]
Other
Very common (10% or more): Fatigue (up to 59%), asthenia (up to 21%), pyrexia (up to 18%), chills (up to 17%), influenza-like illness (up to 16%), pain
Common (1% to 10%): Chest pain[Ref]
Nervous system
Very common (10% or more): Headache (up to 36%), dizziness
Common (1% to 10%): Disturbance in attention, migraine, memory impairment[Ref]
Gastrointestinal
Very common (10% or more): Nausea (up to 34%), diarrhea (up to 12%), vomiting
Common (1% to 10%): Increased lipase, abdominal discomfort, constipation, dyspepsia, dry mouth, gastroesophageal reflux[Ref]
Increased lipase (greater than 3 times the upper limit of normal [3 x ULN]) was reported in up to 2% of patients. Lipase elevation was isolated and asymptomatic.[Ref]
Hematologic
Very common (10% or more): Decreased hemoglobin (up to 32.5%), anemia (up to 21%), neutropenia (up to 17%), decreased neutrophils (up to 15%), decreased lymphocyte count, decreased platelet count
Uncommon (0.1% to 1%): Pancytopenia[Ref]
Decreased hemoglobin (less than 10 g/dL: up to 23%; less than 8.5 g/dL: up to 2%), decreased neutrophils (0.5 to less than 0.75 x 10[9]/L: up to 15%; less than 0.5 x 10[9]/L: up to 5%), and decreased platelets (25 to less than 50 x 10[9]/L: up to 1%) have been reported.
In a study in liver transplant recipients, decreased hemoglobin was very common during therapy. Hemoglobin decreased to less than 10 g/dL in 13 of 40 patients (32.5%); hemoglobin decreased to less than 8.5 g/dL in 1 of those patients. Epoetin and/or a blood product was used in 8 patients (20%); 5 patients (12.5%) discontinued, modified, or interrupted therapy due to side effects.
Pancytopenia was reported, particularly in patients using concomitant pegylated interferon.[Ref]
Dermatologic
Very common (10% or more): Pruritus (up to 27%), rash (18%)
Common (1% to 10%): Alopecia, dry skin
Frequency not reported: Stevens-Johnson syndrome
Postmarketing reports: Skin rashes (sometimes with blisters or angioedema-like swelling), angioedema[Ref]
Psychiatric
Severe depression was reported, particularly in patients with history of psychiatric illness.[Ref]
Very common (10% or more): Insomnia (up to 25%), irritability (up to 13%)
Common (1% to 10%): Depression, anxiety, agitation
Uncommon (0.1% to 1%): Severe depression (including suicidal ideation, suicide)[Ref]
Cardiovascular
Severe bradycardia and heart block have been reported when sofosbuvir-containing regimens were used in combination with amiodarone and/or other agents that lower heart rate.
Serious symptomatic bradycardia has been reported in patients taking amiodarone who started therapy with a regimen containing this drug.[Ref]
Frequency not reported: Severe bradycardia, heart block
Postmarketing reports: Symptomatic bradycardia (including cases requiring pacemaker intervention)[Ref]
Metabolic
Very common (10% or more): Decreased appetite (up to 18%)
Common (1% to 10%): Decreased weight[Ref]
Musculoskeletal
Increased creatine kinase (at least 10 x ULN) was reported in up to 2% of patients. Creatine kinase elevation was isolated and asymptomatic.[Ref]
Very common (10% or more): Myalgia (up to 14%), arthralgia
Common (1% to 10%): Increased creatine kinase, back pain, muscle spasms[Ref]
Respiratory
Very common (10% or more): Dyspnea, cough
Common (1% to 10%): Nasopharyngitis, exertional dyspnea[Ref]
Hepatic
Increased total bilirubin (greater than 1.5 x ULN) was reported in up to 3% of patients. Bilirubin levels peaked during the first 1 to 2 weeks of therapy then decreased and returned to baseline levels by 4 weeks after therapy. These bilirubin elevations were not associated with transaminase elevations.[Ref]
Common (1% to 10%): Increased total bilirubin
Postmarketing reports: Hepatitis B reactivation[Ref]
Ocular
Common (1% to 10%): Blurred vision[Ref]
Frequently asked questions
- What are the new drugs for the treatment of hepatitis C?
- What is the cost of Sovaldi? Why is it so expensive?
- What is the difference between Sovaldi and Harvoni?
More about sofosbuvir
- Check interactions
- Compare alternatives
- Reviews (50)
- Dosage information
- During pregnancy
- Drug class: miscellaneous antivirals
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. Product Information. Sovaldi (sofosbuvir). Gilead Sciences. 2013.
2. Cerner Multum, Inc. UK Summary of Product Characteristics.
3. Cerner Multum, Inc. Australian Product Information.
4. FDA. U.S. Food and Drug Administration. FDA Drug Safety Communicaation: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni or Sovaldi) in combination with another Direct Acting Antiviral drug. ht 2015.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.